GCG and pancreatic neoplasm: This systematic review and meta‐analysis analysed 62 studies, with a total of 66,232 patients at a mean follow‐up of 43.5 weeks, to evaluate the rates of pancreatitis and pancreatic cancer among patients taking GLP‐1 RAs.